‘The next big thing’: Newfund raises €60m to back brain technologies

2026-04-14 · Source: Sifted · Field: Finance & Economics — Capital Markets & Investment Management, Health & Medical Research · Depth: Fundamental Awareness, quick

Summary

Paris-based early-stage VC firm Newfund has closed a new €60m fund specifically dedicated to brain technologies, aiming to invest in a rapidly expanding market. This fund will support up to 25 European startups, primarily in seed rounds with investments ranging from $1m to $3m, across fields like neurology and psychiatry. Newfund is one of the few European VCs exclusively focused on this sector, which saw €4.2bn in global funding in 2025, with 85% going to US startups. The firm emphasizes the exceptional nature of European neuroscience and plans to help its portfolio companies expand into the US market, where M&A activity is strong and FDA approval is crucial for acquirers. Nine companies have already received funding, with eight commercializing in the US and two having secured FDA approval, including Soihtu Dtx and Diagnoly.

Key takeaway

For entrepreneurs developing brain technologies in Europe, you should prioritize strategies for US market entry and FDA approval. Newfund's €60m fund signals strong investor interest in companies that can demonstrate a clear path to commercialization and regulatory compliance in the US, where M&A opportunities are more abundant. Focus on building solutions that address brain diseases, from pharmaceutical research to improved care pathways, to attract specialized VC funding.

Key insights

Brain technologies represent a significant growth opportunity, driven by scientific maturity and advanced tools like AI.

Principles

• European neuroscience offers exceptional academic foundations.
• US market expansion is critical for brain tech startup growth.

Method

Newfund invests in European brain tech startups at seed stage, providing $1M-$3M, with a condition for US market entry and FDA approval.

In practice

• Target FDA approval for US market entry.
• Leverage AI for data insights in brain research.

Topics

• Brain Technologies
• Venture Capital
• Neuroscience
• Healthtech M&A
• FDA Approval

Best for: Investor, Entrepreneur, Tech Journalist

Related on AIssential

• Inside EQT’s plan for the EU’s €5bn superfund: ‘We have over 100 companies in the pipeline’ — The EU's €5bn Scaleup Europe Fund, managed by EQT, aims to retain European tech talent and growth by providing crucial late-stage capital.
• NEURA Robotics secures up to $1.4B, Bending Spoons files for US IPO, and UK PM unveils £400M chip plan — European tech saw significant funding, M&A, and strategic government investments across diverse sectors this week.
• French Tech Funding Wire February 9: Macron's €30M AI Meme; newcleo €75M Round Leads 13 Deals For €175M — France is significantly investing in AI and deep tech, despite isolated criticisms of specific grant figures.
• Europe’s startups should stop chasing grants — Early reliance on public grants distorts startup development, prioritizing funding criteria over market validation.
• European tech funding rebounds to €10.5B in May as mega-rounds power market recovery — European tech funding surged in May 2026, driven by mega-rounds in infrastructure, AI, and cloud, despite fewer deals.
• A Sputnik moment: China's beating the US in neuroscience — China's rapid neurotechnology advancements, driven by national priority and faster regulation, challenge US scientific preeminence.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Sifted.